Cognitive and behavioral dysfunction in Parkinson's disease

Neurochemical and clinicopathological contributions

D. J. Zgaljardic, N. S. Foldi, J. C. Borod

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

The cognitive and behavioral sequelae (i.e., nonmotor profile) of Parkinson's disease (PD), with executive dysfunction and depression being most prominent, have typically been overshadowed due to an emphasis on motor symptomatology. The apparent categorization of PD as a disorder isolated to the dopaminergic system may be a generalization of the disease pathology. Dopamine therapy, used for the treatment of motor symptoms, has not consistently been shown to resolve nonmotor impairments. Research evidence indicates that nondopaminergic neurotransmitter systems (i.e., serotonergic, noradrenergic, & cholinergic) are disrupted in PD and may contribute to cognitive and behavioral dysfunction. Furthermore, Lewy bodies within cortical and subcortical structures can add to the nonmotor profile in PD. Pharmacological interventions for the treatment of cognitive and behavioral impairments associated with PD are few, especially for nondemented patients. The current review of the literature highlights evidence that associates nonmotor dysfunctions with neurochemical and clinicopathological correlates of PD.

Original languageEnglish (US)
Pages (from-to)1287-1301
Number of pages15
JournalJournal of Neural Transmission
Volume111
Issue number10-11
DOIs
StatePublished - Oct 2004
Externally publishedYes

Fingerprint

Parkinson Disease
Lewy Bodies
Cholinergic Agents
Neurotransmitter Agents
Cognitive Dysfunction
Dopamine
Therapeutics
Pharmacology
Depression
Pathology
Research

Keywords

  • Behavior
  • Cognition
  • Dementia
  • Lewy bodies
  • Neurotransmitters
  • Parkinson's disease

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Cognitive and behavioral dysfunction in Parkinson's disease : Neurochemical and clinicopathological contributions. / Zgaljardic, D. J.; Foldi, N. S.; Borod, J. C.

In: Journal of Neural Transmission, Vol. 111, No. 10-11, 10.2004, p. 1287-1301.

Research output: Contribution to journalArticle

Zgaljardic, D. J. ; Foldi, N. S. ; Borod, J. C. / Cognitive and behavioral dysfunction in Parkinson's disease : Neurochemical and clinicopathological contributions. In: Journal of Neural Transmission. 2004 ; Vol. 111, No. 10-11. pp. 1287-1301.
@article{e19d0c30db65462cb5ed4da72bb7740c,
title = "Cognitive and behavioral dysfunction in Parkinson's disease: Neurochemical and clinicopathological contributions",
abstract = "The cognitive and behavioral sequelae (i.e., nonmotor profile) of Parkinson's disease (PD), with executive dysfunction and depression being most prominent, have typically been overshadowed due to an emphasis on motor symptomatology. The apparent categorization of PD as a disorder isolated to the dopaminergic system may be a generalization of the disease pathology. Dopamine therapy, used for the treatment of motor symptoms, has not consistently been shown to resolve nonmotor impairments. Research evidence indicates that nondopaminergic neurotransmitter systems (i.e., serotonergic, noradrenergic, & cholinergic) are disrupted in PD and may contribute to cognitive and behavioral dysfunction. Furthermore, Lewy bodies within cortical and subcortical structures can add to the nonmotor profile in PD. Pharmacological interventions for the treatment of cognitive and behavioral impairments associated with PD are few, especially for nondemented patients. The current review of the literature highlights evidence that associates nonmotor dysfunctions with neurochemical and clinicopathological correlates of PD.",
keywords = "Behavior, Cognition, Dementia, Lewy bodies, Neurotransmitters, Parkinson's disease",
author = "Zgaljardic, {D. J.} and Foldi, {N. S.} and Borod, {J. C.}",
year = "2004",
month = "10",
doi = "10.1007/s00702-004-0178-z",
language = "English (US)",
volume = "111",
pages = "1287--1301",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer Verlag",
number = "10-11",

}

TY - JOUR

T1 - Cognitive and behavioral dysfunction in Parkinson's disease

T2 - Neurochemical and clinicopathological contributions

AU - Zgaljardic, D. J.

AU - Foldi, N. S.

AU - Borod, J. C.

PY - 2004/10

Y1 - 2004/10

N2 - The cognitive and behavioral sequelae (i.e., nonmotor profile) of Parkinson's disease (PD), with executive dysfunction and depression being most prominent, have typically been overshadowed due to an emphasis on motor symptomatology. The apparent categorization of PD as a disorder isolated to the dopaminergic system may be a generalization of the disease pathology. Dopamine therapy, used for the treatment of motor symptoms, has not consistently been shown to resolve nonmotor impairments. Research evidence indicates that nondopaminergic neurotransmitter systems (i.e., serotonergic, noradrenergic, & cholinergic) are disrupted in PD and may contribute to cognitive and behavioral dysfunction. Furthermore, Lewy bodies within cortical and subcortical structures can add to the nonmotor profile in PD. Pharmacological interventions for the treatment of cognitive and behavioral impairments associated with PD are few, especially for nondemented patients. The current review of the literature highlights evidence that associates nonmotor dysfunctions with neurochemical and clinicopathological correlates of PD.

AB - The cognitive and behavioral sequelae (i.e., nonmotor profile) of Parkinson's disease (PD), with executive dysfunction and depression being most prominent, have typically been overshadowed due to an emphasis on motor symptomatology. The apparent categorization of PD as a disorder isolated to the dopaminergic system may be a generalization of the disease pathology. Dopamine therapy, used for the treatment of motor symptoms, has not consistently been shown to resolve nonmotor impairments. Research evidence indicates that nondopaminergic neurotransmitter systems (i.e., serotonergic, noradrenergic, & cholinergic) are disrupted in PD and may contribute to cognitive and behavioral dysfunction. Furthermore, Lewy bodies within cortical and subcortical structures can add to the nonmotor profile in PD. Pharmacological interventions for the treatment of cognitive and behavioral impairments associated with PD are few, especially for nondemented patients. The current review of the literature highlights evidence that associates nonmotor dysfunctions with neurochemical and clinicopathological correlates of PD.

KW - Behavior

KW - Cognition

KW - Dementia

KW - Lewy bodies

KW - Neurotransmitters

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=7944228088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7944228088&partnerID=8YFLogxK

U2 - 10.1007/s00702-004-0178-z

DO - 10.1007/s00702-004-0178-z

M3 - Article

VL - 111

SP - 1287

EP - 1301

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 10-11

ER -